drugset / Trial / NCT01656382

Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex

NCT01656382

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if initial therapy with ABLC at 10/mg/kg/d for 7 days are at least effective as ABLC at 5.0 mg/kg/d X 14 days as induction treatment of patients with disseminated cryptococcosis and HIV.

Timeline

Start
2007-01
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Amphotericin B Unknown 5 mg/kg
Subject Amphotericin B Unknown 10 mg/kg

Indications